Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 27: 1417-1420, 1981;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCann, D. S.
Right arrow Articles by Sorkin, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCann, D. S.
Right arrow Articles by Sorkin, R. P.

Clinical Chemistry, Vol 27, 1417-1420, Copyright © 1981 by American Association for Clinical Chemistry

Radioimmunoassay for plasma thromboxane B2

DS McCann, J Tokarsky and RP Sorkin

Platelet activity may play a major role in the acute phase of atherosclerotic cardiovascular disease. To assess such activity, an assay for plasma thromboxane B2, a prostaglandin metabolite unique to platelets, is needed. The radioimmunoassay described here is based on a nonequilibrium incubation followed by a solid-phase second-antibody separation of bound from free thromboxane B2. No prior purification is required. Values for 22 normal subjects averaged 39.0 (SD 24.6) ng/L. The thromboxane B2 concentration of a plasma sample was 20.3 ng/L as compared with 37 micrograms/L in the corresponding serum. Plasma thromboxane B2 concentrations before and after ingestion of aspirin differed significantly (p less than 0.025). The biological half-life of intravenously injected [3H]thromboxane B2 in rabbits was 20 min. At the end of 2 h, 85% of the label was accounted for in urine, 7% in liver, and 5% in lung. Our assay is simple, reproducible, sensitive, and specific. It can be used to reflect acute events involving platelet aggregation.


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
K. Morioka, R. Muraoka, Y. Chiba, A. Ihaya, T. Kimura, H. Noguti, and T. Uesaka
LEUKOCYTE AND PLATELET DEPLETION WITH A BLOOD CELL SEPARATOR: EFFECTS ON LUNG INJURY AFTER CARDIAC SURGERY WITH CARDIOPULMONARY BYPASS
J. Thorac. Cardiovasc. Surg., January 1, 1996; 111(1): 45 - 54.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by the American Association for Clinical Chemistry.